Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02863510
Other study ID # 2012138RN
Secondary ID
Status Completed
Phase N/A
First received February 12, 2016
Last updated August 8, 2017
Start date September 2013
Est. completion date July 2016

Study information

Verified date August 2017
Source Heart of England NHS Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A pilot, single-center, prospective, interventional study. The objective is to demonstrate that catheter-based renal denervation using carbon dioxide renal angiography in patients with moderate to severe chronic kidney disease can be performed for treatment of uncontrolled hypertension.


Description:

Renal sympathetic denervation has been shown to be safe and effective in patients with uncontrolled hypertension and estimated Glomerular Filtration Rate (eGFR)>45 mL/min per 1•73 m². However, the safety and efficacy of this has not been studied in patients with more severe renal impairment. The investigators aim to examine safety and efficacy of renal denervation (RDN) in patients with eGFR between 44 and 15 ml/min/1.73 m2 (CKD 3b & 4) in a pilot study which may be a precursor of a large observational study in the future. Moreover, the current imaging protocol and procedure protocol for renal sympathetic denervation requires the use of iodinated contrast, which can have deleterious effects on renal function. The investigators have a proven track record for the use of carbon dioxide angiography in renal artery intervention. The investigators would like to use carbon dioxide angiography in this study to minimize contrast induced deterioration in renal function in this cohort which may again be a precursor of a farther larger study.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date July 2016
Est. primary completion date July 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Patients aged 18-75 years with a clinic systolic blood pressure of 140 mm Hg or more despite compliance with three or more antihypertensive drugs,

- eGFR<45 and >15 mL/min per 1.73 m².

Exclusion Criteria:

- eGFR <15 mL/min per 1.73 m²,

- Type 1 diabetes,

- Substantial stenotic valvular heart disease,

- Pregnancy or planned pregnancy during the study,

- A history of myocardial infarction, unstable angina, or cerebrovascular accident in the previous 6 months.

Study Design


Intervention

Device:
Renal Sympathetic Denervation
Renal sympathetic denervation is a minimally invasive, endovascular catheter-based procedure using radiofrequency ablation of sympathetic nerves located in the walls of renal arteries, aimed at treating treatment-resistant hypertension.

Locations

Country Name City State
United Kingdom Heart of England NHS Foundation Trust Birmingham West Midlands

Sponsors (1)

Lead Sponsor Collaborator
Heart of England NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Estimated glomerular filtration rate from baseline to 7 days and 30 days Change in eGFR from baseline to 7 days and 1 month as measure of safety in terms of kidney function at baseline, 7days and 30 days
Secondary Change in estimated glomerular filtration rate from baseline to 7 days, 1, 3, and 6 months Change in kidney function from baseline to 7 days, 1, 3, and 6 months at baseline, 7 days, 1, 3, and 6 months
Secondary Change in proteinuria (albumin:creatinine ratio) from baseline to at 1, 3, and 6 months. Change in proteinuria (albumin:creatinine ratio) from baseline to at 1, 3, and 6 months. at baseline, 1, 3, and 6 months
Secondary Change in mean daytime ambulatory blood pressure on 24 hour monitoring from baseline to 6 months Change in mean daytime ambulatory blood pressure on 24 hour monitoring from baseline to 6 months at baseline and 6 months
Secondary Change in office blood pressure from baseline to 1,3, and 6 months Change in office BP from baseline to 1,3, and 6 months for efficacy at baseline, 1, 3, and 6 months
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A